Hims & Hers CEO Andrew Dudum said in statement posted on X that the company will continue to offer access to personalized treatments "as allowed by law to meet patient needs." "Were also closely monitoring potential future shortages, as Novo Nordisk stated two weeks ago that it would continue to have 'capacity limitations' and 'expected continued periodic supply constraints and related drug shortage notifications,'" Dudum said
Lee MS, Clarke C, Jiang Z, Manyam GC, Tian F, Lu Y, Morris J, Broom BM, Menter D, Vilar Sanchez E, Shureiqi I, Raghav KPS, Eng C, Chang GJ, Simon I, Bernards R, Mills GB, Overman MJ, Maru DM, Kopetz S
Other DPP-4 inhibitors have not been thoroughly studied but may also be affected by grapefruit
Duration of Deficiency: Chronic deficiencies may require more extended treatment to replenish depleted stores
Studies are discussed that have employed anti-oxidants compounds as therapeutics to improve oocyte and embryo quality in infertile subjects, and improve fertility in patients with endometriosis
Tirzepatide has shown slightly higher average weight loss in head-to-head trials, but it's also typically more expensive and may have a different side effect profile
